Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference

New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism

ANN ARBOR, MI / ACCESSWIRE / June 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA® Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms.

The presentation, "Evaluation of a Feline-Optimized TSH Assay in Cats with Hyperthyroidism and with Non-Thyroidal Illness," will be given by Dr. Camille Brassard, DVM, IPSAV (Virginia-Maryland Regional College of Veterinary Medicine), at the American College of Veterinary Internal Medicine (ACVIM) Forum being held in Minneapolis, MN June 6 - 8, 2024.

Dr. Stefanie DeMonaco, DVM, MS, DACVIM (SAIM), Associate Professor of Veterinary Clinical Sciences at Long Island University and the supervisor of the research study, for which Zomedica provided materials and funding, stated, "The BAW system has greater sensitivity at low ranges than CLIA systems, which have been optimized for canine diagnosis. While CLIA systems lack the sensitivity to correctly diagnose all hyperthyroid cats, this study confirms that the BAW system will correctly diagnose hyperthyroidism even in the presence of confounding non-thyroid illness (NTI)."

The TRUFORMA diagnostic platform utilizes unique proprietary BAW technology that provides highly precise and sensitive measurements at levels that other optical-based diagnostic methods do not achieve. Currently, TRUFORMA in-clinic diagnostic systems provide accurate, rapid, and reliable diagnostic results to veterinarians, assisting in their diagnosis and treatment of complex thyroid and adrenal conditions, canine non-infectious gastrointestinal disease, and equine Cushing's disease - all providing reference lab quality with point-of-care convenience. Zomedica anticipates introducing additional veterinary assays to the market, further enabling reference lab quality with point-of-care convenience.

Dr. DeMonaco recently initiated two additional studies in collaboration with Zomedica, further highlighting the need to utilize the BAW platform for properly diagnosing and monitoring hyperthyroid cats. These studies include:

TSH in cats with illness and as predictor of survivability

TSH as a predictor of outcome in hyperthyroid cats treated with radioiodine therapy

"Previous research has shown that the extended dynamic range of the TRUFORMA TSH assay utilizing BAW technology allows highly accurate quantification across a wide range of Thyroid Stimulating Hormone (TSH) concentrations, which is particularly vital for accurate diagnosis of feline thyroid disease," said Ashley Wood, PhD, Zomedica's Vice President of Research & Development. "This follow-up research confirms that TRUFORMA's results correctly differentiate between cases of thyroid disease and non-thyroid illness."

Zomedica is also sponsoring two additional educational presentations at ACVIM, "Hyperadrenocorticism Diagnostic Testing and Interpretation in Dogs" by Dr. Julie Byron, and "Gastrointestinal Blood Panels" by Dr. Gary Oswald.

Adrian Lock, Zomedica's Vice President of Clinical & Veterinary Affairs, stated, "Zomedica is fully committed to the development and validation of new, highly beneficial point-of-care assays for the TRUFORMA platform, as well as the education of veterinary professionals about the many ways we are advancing techniques and technologies for diagnostics, monitoring, and therapeutics. Zomedica places a top priority on collaborating with veterinary researchers to advance animal healthcare."

Zomedica remains committed to advancing animal care through innovation and research, maintaining its position at the forefront of veterinary diagnostics and therapeutics. The total addressable market for Zomedica's diagnostic and therapeutic products is estimated at $2.5 billion annually. The Company's potential customer base for TRUFORMA installations is expansive, including approximately 4,450 equine or mixed veterinary practices and 30,000 small animal veterinary practices across the United States, in a veterinary services market estimated at $62 billion.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://m.facebook.com/zomedica
• X (formerly Twitter): https://twitter.com/zomedica
• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: continued growth of sales, the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work including the development of new cartridges; uncertainty as to the timing and results of verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.